ADMEcell Will Be Exhibiting At The AAPS Meeting Oct 24-27 Booth #1559

Posted by Sandy Koshkin on Thu, Oct 13, 2011 @ 11:50 AM

ADMEcell To Exhibit At The AAPS Meeting IN Washington DC Oct 25-27

ADMEcell will join over 500 exhibitors at the upcoming AAPS meeting in Washinton DC October 25 through October 27.  This is the 25th anniversary of the AAPS meeting which will include speakers such as Janet Woodcock, M.D., director of the Center for Drug EvaluatioAAPS Meetingn and Research at the Food and Drug Administration, who will provide her view on the future of regulations. John Lechleiter, Ph.D., president and chief executive officer, Eli Lilly and Company, will speak to the future shape of the global pharmaceutical industry; Francis S. Collins, M.D., Ph.D., director, U.S. National Institutes of Health, will speak on current research that may lead to new therapies in the future. Sir Michael Rawlins, M.D., chairman of the National Institute of Health & Clinical Excellence (NICE) of the United Kingdom, will speak on the cost benefits of therapies and the societal ability to pay for the therapies, "Value for Money in Healthcare: The Future." NICE is an independent organization responsible for providing national guidance on promoting good health and preventing and treating ill health.

ADMEcell will showcase its three product lines for providing tools for drug discovery and development:

Cell based Assays: Caco-2, MDR-1, BCRP & BBB Permeability

ELISA Kits For Monoclonal Antibody Assessment: Quantification kits for Human, Mouse, Rat & Bovine IgG and Mouse Ig Isotyping

Protein Binding Kits For HAS and AGP

Please plan to visit us at Exhibit #1559

Tags: transporters, ELISA Kits, Human IgG Kits, Mouse IgG Kits, Rat Igg Kits, Mouse Isotyping Kits, Ready To Use Assays, Ready To Use Kits, aaps meeting, aaps exhibition, caco-2 assay, cell based assays, MDR1 Kits, Protein Binding Kits, Blood Brain Absorption Kits, Caco-2 Kits

Overview of ADME-Tox Market Emphasis On In-Vitro Kits

Posted by Sandy Koshkin on Thu, Sep 22, 2011 @ 04:03 PM

Caco Monolayer 

The ADME Tox in vitro human testing market is estimated at over $500 million in 2011 with a healthy growth rate over 15% per year through 2015.  This market is made up of CYP450 inhibition assays, human PK predictive assays, Liver Hepatocytes and Cell-Based Assays such as Caco-2, MDR-1  BCRP and BBB (Blood Brain Barrier), to name a few (  The largest share of the market is Hepatocytes testing as they closely resemble the in vivo testing. Currently, Pharma and Biotech companies rely heavily on making these assays in house. With Ready To Use Assay Kits for common applications such as Caco-2, MDR-1, BCRP and BBB, the  Pharma and Biotech companies could save enormous amounts of time and resources in their drug discovery and development processes.

The future of Ready-to-Use In Vitro Assay Kits is bright.  Additional assay development in the drug transporters field will lead to more available Ready to Use Kits.

Tags: transporters, ELISA Kits, Human IgG Kits, in vitro, in vitro assays, cell based assays, in vitro models caco-2 assay, MDR1 Kits

DMPK Labs and Integrating New In-Vitro Assays

Posted by Sandy Koshkin on Thu, Aug 04, 2011 @ 04:45 PM

DMPK Labs and Integrating New In Vitro Assays

Improve DMPK Productivity by Using the Industry Leading Solution

Determining the Drug Metabolism and PharmacoKinetic properties of a drug is crucial to understanding its safety and efficacy before the regulatory approval process takes place.

Currently, DMPK Labs have a tremendous balancing act on their hands betweenMDR1 Plated Cells getting all the routine work completed with minimal staff and deciding on handling selected new compounds. Many of these compounds can be tested in house or contracted out to CRO.  Preparing reagents and developing in-house assays require time and resources, whereas waiting for data from an outside source uses very little resources other than money. However, Ready-to-Use Assay Kits offer a simple solution to balance the resources needed and the associated costs.

So, how does a lab begin to evaluate a newer technology such as a new in vitro assay that can be very helpful long term? In the short term, it seems like there is no time available…However, the benefits  for DMPK labs are enormous  if they can dedicate some time to evaluate for example, a Ready-To-Use cell based assay such as Caco-2 or MDCR1 or Plasma Protein Binding to compare the cost and time savings with their current methods. These assays are available at a reasonable price and produce speedy and reliable results to make the life  easier in the DMPK Labs.

Tags: transporters, ELISA Kits, Human IgG Kits, Mouse IgG Kits, Ready To Use Assays, Ready To Use Kits, caco-2 assay, cell based assays, MDR1 Kits, Protein Binding Kits, Blood Brain Absorption Kits, Caco-2 Assays

First ADMEcell Blog

Posted by Sandy Koshkin on Tue, Jul 05, 2011 @ 08:56 PM

Welcome to the ADMEcell Blog. As part of our efforts to keep you updated on new developments at ADMEcell, we will be updating this space with product news and special offers from our Executive and Sales teams and new findings, technological news and “Posts from the Bench” from our Lab staff.

ADMEcell, Inc., a life science Company located in the San Francisco Bay Area, was established in October 2008 to develop and market unique and proprietary Ready-to-Use Products that accelerate drug discovery and development processes. The ADMEcell management team combines many years of solid experience in product research, development and marketing in diverse areas of biotechnology, including Molecular Diagnostics, Infectious Diseases, Oncology and Immunodiagnostics.  For more details on the management team’s experience and background, please visit:

ADMEcell’s Ready-to-Use product line includes three major categories:

*CacoReady: and related products: – State of the art cell-based assays, providing ease of use and a cost effective in-vitro technology for evaluation of oral absorption efficiency, compound screening, oral bioavailability, mechanisms of oral/intestinal absorption, oral toxicity and transporter studies – all without in-house cell line development, acquisition or propagation;

*TRANSIL Brain Absorption, Intestinal Absorption and Plasma Protein Binding products: – Fast and high-throughput assays for brain tissue binding, brain disposition and plasma protein binding of compounds (including very sticky and tightly bound compounds);

*FastELYSA Antibody Screening products: – Fast and simple ELISA-based assays for quantification of immunoglobulin G from human and other species, screening of high producing clones, monitoring antibody production, transient transfection and characterization of mouse monoclonal isotypes.

You can always follow us on Twitter @ADMEcell or visit our Facebook page at: for the latest updates on our technology and products. Visit our main website at or send us an e-mail at

The ADMEcell Management Team 

Tags: transporters, caco-2 assay, cell based assays